This article has Open Peer Review reports available.
Unusual gastric mucosal infiltration by a medullary thyroid carcinoma: a case report
© The Author(s). 2016
Received: 6 April 2016
Accepted: 28 June 2016
Published: 27 July 2016
Medullary thyroid carcinoma accounts for approximately 1 to 2 % of all thyroid carcinoma cases. The most common route of dissemination is to locoregional lymph nodes. Distant metastases commonly affect bones, lungs, and liver. We present a case of a white woman with a 25-year history of medullary thyroid carcinoma on multiple medications including tyrosine kinase inhibitor therapy for the last 11 months, who exhibited unusual diffuse infiltration of advanced stage medullary thyroid carcinoma to her gastric mucosa.
A 53-year-old white woman presented with increasing fatigue, loss of appetite, and severe epigastric pain radiating to her back. She had a history of medullary thyroid carcinoma (pT2pN1b), diagnosed 25 years ago and treated by complete thyroidectomy and repeated bilateral cervical lymph node dissection. Medical therapy included octreotide 20 mg every 4 weeks, which was switched to the tyrosine kinase inhibitor vandetanib 300 mg/day 11 months ago when computed tomography scanning revealed progressive mediastinal lymph node and diffuse and symptomatic pulmonary metastases. Of note, she demonstrated macroscopically stable pulmonary and mediastinal lymph node metastases; however, her calcitonin serum levels dramatically increased. Computed tomography scanning revealed a single new intrahepatic lesion (4 mm) as well as multiple (>10) new supraclavicular lesions suggestive of medullary thyroid carcinoma progress. As proven by gastric biopsy and immunohistochemical evaluation, her epigastric pain was explained by a diffuse infiltration of her gastric mucosa by metastatic medullary thyroid carcinoma. Subsequently, she rapidly deteriorated and died.
The current case report shows for the first time an unusual metastatic infiltration of the gastric mucosa by medullary thyroid carcinoma. When treating these patients, it is important to include this differential diagnosis during follow-up.
Thyroid cancer overall represents a rare tumor entity, however, the incidence of thyroid cancer has recently been constantly increasing [1, 2]. Within this heterogeneous group of tumors, differentiated thyroid cancer represents the majority (approximately 90 %) of all newly diagnosed thyroid cancer cases . Medullary thyroid carcinoma (MTC) accounts for approximately 1 to 2 % of all thyroid carcinoma cases, and at diagnosis 7 to 23 % of all patients demonstrate metastatic disease [1, 4]. Overall, 10-year disease-specific survival rates average approximately 75 % with a strong dependency on tumor stage (averaging 21 % in stage IV tumors). Metastases are commonly found in the lymph nodes, while distant metastatic disease is found in lungs, bone, and liver, and, more rarely, in brain, skin, and breast [5, 6]. Therapeutically, the recent introduction of tyrosine kinase inhibitor therapy (vandetanib, cabozantinib) has led to a significant improvement of the prognosis in patients with rapidly progressive and advanced stage MTC .
A 53-year-old white woman presented with increasing fatigue, loss of appetite, and severe epigastric pain radiating to her back. She had a history of MTC (pT2pN1b), diagnosed 25 years ago and treated by complete thyroidectomy and bilateral cervical lymph node dissection, followed by repeated surgical resection of lymph node metastases 19 and 12 years ago. No further specific treatment modalities (for example radiotherapy) had been employed. No genetic analysis had been performed for germline or somatic RET proto-oncogene mutations, nor for other somatic mutations (HRAS, KRAS, NRAS). On clinical examination, however, there was no indication of other manifestations of multiple endocrine neoplasia type 2 (MEN2), especially no clinical signs of pheochromocytoma. Since data on the RET proto-oncogene status have been missing in our patient, no risk category (moderate, high, highest) according to the revised American Thyroid Association Guidelines for the management of MTC  had been assigned. However, based on the American Joint Committee on Cancer (AJCC) TNM-Classification, the MTC had been a stage IV A tumor (pT2pN1b) at the time of the initial complete thyroidectomy in our patient. Post complete thyroidectomy, she had hypoparathyroidism, which was treated with calcium and calcitriol. She received levothyroxine replacement therapy. Repeated biochemical and clinical evaluations during the course of the disease did not demonstrate any signs of paraneoplastic adrenocorticotropic hormone (ACTH) and/or corticotropin-releasing hormone (CRH) secretion. Medical therapy of the MTC included octreotide 20 mg every 4 weeks, which was switched to the tyrosine kinase inhibitor vandetanib 300 mg/day 11 month ago when computed tomography (CT) scanning revealed progressive mediastinal lymph node and diffuse and symptomatic pulmonary metastases.
Additional laboratory tests revealed a dramatic increase in her basal serum calcitonin levels from 563 pg/ml to 6487 pg/ml within 2 months, indicative of rapid tumor progress of the underlying MTC. Of interest, at the same time she had rather stable carcinoembryonic antigen (CEA) serum levels of 40.7 ng/ml (from 62.3 ng/ml 14 months earlier). Histologic and immunohistochemical analyses of gastric biopsy specimen demonstrated diffuse mucosal infiltration of MTC (Fig. 1d–h) with a KI-67 index of up to 40 %, proving metastatic disease of MTC to the gastric mucosa. Of note, while immunohistochemical analysis of calcitonin was strongly positive (Fig. 1g), staining for CEA demonstrated merely focal and weak staining (Fig. 1h); staining for thyroglobulin remained completely negative (data provided in Additional file 1). She rapidly deteriorated and died due to multiorgan failure before third-line treatment could be initiated.
MTC is sporadic in origin in 60 to 75 % of all patients with MTC, while the others exhibit germline mutations in the RET proto-oncogene, namely patients with multiple endocrine neoplasia type 2A (MEN2A), multiple endocrine neoplasia type 2B (MEN2B), and familial MTC syndrome (FMTC). The most common sites for metastatic disease in MTC are locoregional lymph nodes; these metastases often occur early in the disease process . This was also the case in our patient, who initially presented with a pT2pN1b tumor stage, and who received repeated resection of cervical lymph node metastases during the following years.
However, in advanced MTC, distant metastases have been described. In one report, 74 % of patients demonstrated metastatic disease to the bone , other groups found small hepatic metastases in 25 % of patients with advanced MTC , as well as lung metastases in 35 % of patients with MTC with persistently elevated calcitonin levels after initial treatment . In addition, cases of cutaneous [11, 12], brain , and breast [14, 15] metastases of MTC have been described.
Metastatic disease to the stomach overall is a rare incidence in all cancer types, and data in the literature are based on case reports as well as small case series [16–18]. The most common primary tumors reported to spread to the stomach are melanoma, breast, lung, and esophageal carcinoma as well as renal cell cancer . On clinical examination, gastric metastases present with epigastric pain, nausea, vomiting, as well as gastrointestinal hemorrhage. Mostly solitary lesions within the gastric mucosa are observed, although multiple metastatic lesions have been reported as well . To the best of our knowledge, metastatic disease to the gastric mucosa of a MTC has not yet been reported in the literature.
Our patient had MTC with a follow-up history of 25 years and presented with severe epigastric pain. Multiple lesions within her gastric mucosa were histologically proved to be a diffuse metastatic infiltration of the MTC. Of note, CT scans of her chest and abdomen revealed stable pulmonary and mediastinal lymph node metastases; however, multiple supraclavicular lesions as well as a single new intrahepatic lesion were suggestive of MTC progress. Remarkably, a sharp rise in calcitonin levels was indicative of rapid tumor progression as well, while her serum levels of CEA remained rather stable.
The current case report should raise awareness of unusual gastrointestinal metastatic disease of MTC in advanced disease states, especially with the increasing prognosis of these tumors due to molecular-targeted oncologic therapies (for example tyrosine kinase inhibitors). In treating these patients, it is important to include this generally uncommon differential diagnosis for unspecific patient complaints during follow-up.
ACTH, adrenocorticotropic hormone; AJCC, American Joint Committee on Cancer; CEA, carcinoembryonic antigen; CRH, corticotropin-releasing hormone; CT, computed tomography; FMTC, familial medullary thyroid carcinoma syndrome; MEN2, multiple endocrine neoplasia type 2; MEN2A, multiple endocrine neoplasia type 2A; MEN2B, multiple endocrine neoplasia type 2B; MTC, medullary thyroid carcinoma
We thank the Department of Radiology, Giessen University Hospital, for preparation of the computed tomography scans presented in our manuscript.
No funding agency was involved in our patient’s treatment or our preparation of the manuscript.
Availability of data and materials
The dataset supporting the conclusions of this case report is included within the case report (images and laboratory parameters).
Acquisition, analysis, and interpretation of the data: TK, WD, FCR, AS, RS, and SG. Manuscript preparation: TK and AS. Critical revision and significant intellectual contribution to the manuscript: TK, WD, FCR, AS, RS, and SG. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient’s next-of-kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Ethics approval and consent to participate
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Wells Jr SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610.View ArticlePubMedPubMed CentralGoogle Scholar
- Radespiel-Troger M, Batzler WU, Holleczek B, Luttmann S, Pritzkuleit R, Stabenow R, et al. Rising incidence of papillary thyroid carcinoma in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57(1):84–92.View ArticlePubMedGoogle Scholar
- American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.View ArticleGoogle Scholar
- Schlumberger M, Bastholt L, Dralle H, Jarzab B, Pacini F, Smit JW, et al. 2012 European Thyroid Association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J. 2012;1(1):5–14.View ArticlePubMedPubMed CentralGoogle Scholar
- Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92(11):4185–90.View ArticlePubMedGoogle Scholar
- Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. Clin Oncol. 2010;22(6):475–85.View ArticleGoogle Scholar
- Cabanillas ME, Hu MI, Jimenez C. Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat – and with which drug – those are the questions. J Clin Endocrinol Metab. 2014;99(12):4390–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Maxwell JE, Sherman SK, O’Dorisio TM, Howe JR. Medical management of metastatic medullary thyroid cancer. Cancer. 2014;120(21):3287–301.View ArticlePubMedPubMed CentralGoogle Scholar
- Mirallie E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L, et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab. 2005;90(2):779–88.View ArticlePubMedGoogle Scholar
- Tung WS, Vesely TM, Moley JF. Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery. 1995;118(6):1024–9. discussion 1029–1030.View ArticlePubMedGoogle Scholar
- Nashed C, Sakpal SV, Cherneykin S, Chamberlain RS. Medullary thyroid carcinoma metastatic to skin. J Cutan Pathol. 2010;37(12):1237–40.View ArticlePubMedGoogle Scholar
- Ordonez NG, Samaan NA. Medullary carcinoma of the thyroid metastatic to the skin: report of two cases. J Cutan Pathol. 1987;14(4):251–4.View ArticlePubMedGoogle Scholar
- Borcek P, Asa SL, Gentili F, Ezzat S, Kiehl TR. Brain metastasis from medullary thyroid carcinoma. BMJ case reports. 2010;2010:bcr0920103301. doi:10.1136/bcr.09.2010.3301.View ArticlePubMedPubMed CentralGoogle Scholar
- Marcy PY, Thariat J, Peyrottes I, Dassonville O. Bilateral breast involvement in medullary thyroid carcinoma. Thyroid. 2009;19(2):197–9.View ArticlePubMedGoogle Scholar
- Mandanas S, Margaritidou E, Christoforidou V, Karoglou E, Geranou C, Chrisoulidou A, et al. Breast metastasis from medullary thyroid carcinoma in a male patient: case report and review of the literature. Rare Tumors. 2015;7(2):5765.View ArticlePubMedPubMed CentralGoogle Scholar
- De Palma GD, Masone S, Rega M, Simeoli I, Donisi M, Addeo P, et al. Metastatic tumors to the stomach: clinical and endoscopic features. World J Gastroenterol. 2006;12(45):7326–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Namikawa T, Hanazaki K. Clinicopathological features and treatment outcomes of metastatic tumors in the stomach. Surg Today. 2014;44(8):1392–9.View ArticlePubMedGoogle Scholar
- Weigt J, Malfertheiner P. Metastatic disease in the stomach. Gastrointestinal tumors. 2015;2(2):61–4.View ArticlePubMedPubMed CentralGoogle Scholar